首页|期刊导航|肿瘤防治研究|VIPR2作为食管腺癌免疫浸润及预后生物标志物的生物信息学分析

VIPR2作为食管腺癌免疫浸润及预后生物标志物的生物信息学分析OA

Bioinformatics Analysis of VIPR2 as A Biomarker for Immune Infiltration and Prognosis in Esophageal Adenocarcinoma

中文摘要英文摘要

目的 探讨血管活性肠肽受体2(VIPR2)在食管腺癌(ESAD)中的表达特征、预后价值及其与免疫浸润的相关性.方法 从TCGA数据库获取80例ESAD组织与10例正常组织的转录组数据,结合ImmPort数据库筛选免疫相关差异基因.Cox回归分析评估VIPR2的预后价值,GS-VA、ssGSEA法分析VIPR2与免疫细胞浸润的相关性,并通过GO、KEGG、GSEA进行功能富集分析.结果 VIPR2在ESAD组织中表达显著降低(P<0.05),其高表达与患者总生存期延长显著相关(HR=0.246,P=0.047),为独立预后因子.VIPR2高表达组中CD8+T细胞、NK细胞、DC等15种免疫细胞浸润水平显著升高,Th17细胞比例降低(P<0.05).功能富集分析提示VIPR2参与多条肿瘤免疫相关通路,并与PD-1、CTLA-4表达呈正相关(P<0.01).结论 VIPR2可作为ESAD患者预后评估的潜在生物标志物,并可能参与调控肿瘤免疫微环境.

Objective To investigate the expression characteristics,prognos-tic value,and correlation with immune infiltration of vasoactive intestinal peptide receptor 2(VIPR2)in esophageal adenocarcinoma(ESAD).Methods Transcri-ptome data of 80 ESAD and 10 normal tissues were retrieved from the TCGA database.Immune-related differential genes were identified by integrating the ImmPort database.Cox regression analysis was applied to evaluate the prognostic significance of VIPR2.GSVA and ssGSEA were employed to assess the association between VIPR2 and immune-cell infiltr-ation.Functional enrichment was performed using GO,KEGG,and GSEA.Results VIPR2 expression was significantly down-regulated in ESAD tissues(P<0.05).High VIPR2 expression was associated with prolonged overall survival(HR=0.246,P=0.047),serving as an independent prognostic factor.Fifteen immune-cell types,including CD8+T cells,NK cells,and dendritic cells,showed significantly higher infiltration in the VIPR2-high group,whereas Th17-cell abundance was decre-ased(P<0.05).Enrichment analyses revealed that VIPR2 par-ticipated in multiple tumor-immune pathways and was posi-tively correlated with PD-1 and CTLA-4 expression(P<0.01).Conclusion VIPR2 may serve as a potential biomarker in the prognostic assessment and could modulate the tumor-immune microenvironment in ESAD.

赵珂;刘磊;王桂阁;张家齐;杨丽冰;郭超;黄诚;陈野野;李单青

100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科100730 北京,中国医学科学院北京协和医学院北京协和医院胸外科

医药卫生

食管腺癌VIPR2免疫浸润生物标志物预后生物信息学

Esophageal adenocarcinomaVIPR2Immune infiltrationBiomarkerPrognosisBioinformatics

《肿瘤防治研究》 2026 (6)

430-439,10

中国医学科学院医学与健康科技创新工程项目(2023-I2M-C&T-B-019)中央高水平医院临床科研业务费(2025-PUMCH-A-177) Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(No.2023-I2M-C&T-B-019)National High Level Hospital Clinical Research Funding(No.2025-PUMCH-A-177)

10.3971/j.issn.1000-8578.2026.25.0871

评论